Abstract
Nevirapine associated rash has been well described in the Caucasian population. With increasing access to antiretroviral treatment--especially a fixed dose combination--by people living with HIV/AIDS in developing countries, there is a need to emphasize the lead in doses of nevirapine. We strongly recommend a warning label on the bottle advising patients on the lead-in period and the signs and symptoms of significant rash.